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1. INTRODUCTION: 
The concept of validation was first proposed by two 
Food and Drug Administration officers, Ted Byers and 
Bud Loftus, in the mid 1970’s in order to improve the 
quality of pharmaceuticals. Pharmaceutical Process 
Validation is the most important and recognized 
parameters of CGMPs.
1
 The requirement of process 
validation appears of the quality system (QS) 
regulation. The goal of a quality system is to 
consistently produce products that are fit for their 
intended use. The process validation is standardization 
of the validation documents that must be submitted with 
the submission file for marketing authorization.
2
 The 
process validation is intended to assist manufacturers in 
understanding quality management system(QMS) 
requirements concerning process validation and has 
general applicability to manufacturing process.
3
 
Some Defination of Validation: 
According to FDA, 
4
 
Assurance of product quality is derived from careful 
and systemic attention to a number of importance 
factors, including: selection of quality process through 
in-process and end-product testing.  
According to US FDA in 1978, 
5
 
“A validation manufacturing process is one which has 
been proved to do what it purpose or is represented to 
do. The proof of validation is obtained through the 
collection and evaluation of data, preferably, beginning 
from the process development phase and continuing the 
production phase. Validation necessarily includes 
process qualification (the qualification of materials, 
equipment, system, building, personnel), but it also 
includes the control on the entire process for repeated 
batches or runs”. 
European Commission - 1991 - Validation - “Act of 
proving, in accordance of GMPs that Any” process 
actually leads to expected results. 
European Commission - 2000 - Validation - 
“Documented evidence that the process, operated within 
established parameters, can perform effectively and 
reproducibly to produce a medicinal product meeting its 
predetermined specifications and quality attributes”.6 
WHO guidelines define validation as Validation is 
documented act of proving that any procedure, process, 
equipment, material, activity or system actually leads to 
the expected results. Validation act of proving, in 
accordance of GMPs that any process actually leads to 
expected results. Documented evidence that the process, 
operated with in established parameters, can perform 
effectively reproducibly to produce a medicinal product 
meeting its predetermined specifications and quality 
attributes. 
2. Types of Validation 
7
 
2.1 Analytical Validation 
Analytical validation is the evaluation of product 
quality attributes through testing, to demonstrate 
reliability is being maintained throughout the product 
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life cycle and that the precision, accuracy, specificity, 
LOD, linearity, selectivity, strength, purity and 
specification has not been compromised. The analytical 
method gives the detail steps necessary to perform an 
analysis. This may include: preparation of samples, 
standards and reagents, use of apparatus and use of 
formula for the calculation and many more. 
2.2 Equipment Validation 
Validation of equipments is known as qualification. 
Equipment validation is divided into Installation 
Qualification (IQ), Operational Qualification (OQ), and 
Performance Qualification (PQ). An IQ documents 
specify static attributes of a facility or item to prove that 
the installation of the unit has been correctly performed 
and the installation specifications of the manufacturer 
have been met. After installation it must be ensured that 
the equipment can deliver operating ranges as specified 
in the purchase order. This is called OQ. The PQ is 
concerned with proving the process being done by the 
machine as it is supposed to do. 
2.3 Process Validation 
Process validation is “A documented procedure which 
provides a high degree of assurance that a specific 
process will consistently produce a product meeting its 
predetermined specification and quality attributes”. 
Process validation is divided into different types as 
follows:- 
(a) Prospective validation 
It is defined as the establishment of documented 
evidence that a system does what it purpose to do based 
on preplanned protocol. This approach to validation is 
normally undertaken whenever a new formula, process 
or facility must be validated before commercial routine 
pharmaceutical formulation commences. During the 
product development phase the production process 
should be broken down into individual steps. Each step 
should be evaluated on the basis of experience or 
theoretical considerations to determine the critical 
parameters that may affect the quality of the finished 
product. A series of experiments should be designed to 
determine the criticality of these factors. Each 
experiment should be planned and documented fully in 
an authorized protocol. 
(b) Retrospective validation 
It is defined as the establishment of documented 
evidence that a system does what it purpose to do based 
on review and analysis of historical data. This is 
achieved by the review of the historical manufacturing 
testing data to prove that the process has always 
remained in control. For the purpose of retrospective 
validation studies, it is considered acceptable that data 
from a minimum of ten consecutive batches produced 
be utilized. When less than ten batches are available, it 
is considered that the data are not sufficient to 
demonstrate retrospectively that the process is fully 
under control. In such cases the study should be 
supplemented with data generated with concurrent or 
prospective validation. 
 
(c) Concurrent validation 
It is similar to prospective, except the operating firm 
will sell the product during the qualification runs, to the 
public at its market price. This validation involves in 
process monitoring of critical processing steps and 
product testing. It is the repetition of a validation 
process or a specific part of it. This is carried out when 
there is any change or replacement in formulation, 
equipment, and plant or site location. The justification 
or conducting concurrent validation must be 
documented and the protocol must be approved by the 
Validation Team. A report should be prepared and 
approved prior to the sale of each batch and a final 
report should be prepared and approved after the 
completion of all concurrent batches. It is generally 
considered acceptable that a minimum of three 
consecutive batches within the finally agreed 
parameters, giving the product the desired quality 
would constitute a proper validation of the process. 
(d) Revalidation 
Re-validation is usually performed to the confirmation 
of initial validation for a Periodic review. Re-validation 
provides the evidence that changes in a process and /the 
process environment that are introduced do not 
adversely affect process characteristics and product 
quality.  
2.4 Process/ Product Validation: 
Process Validation is establishing documented evidence 
which provides a high degree of assurance that a 
specific system will consistently produce a product 
meeting its predetermined specifications and quality 
attributes. 
Phases in Process Validation 
Phase1: This is the Pre-validation Qualification Phase 
which covers all activities relating to product research 
and development, formulation pilot batch studies, scale-
up studies, transfer of technology to commercial scale 
batches, establishing stability conditions and storage, 
and handling of in-process and finished dosage forms, 
equipment qualification, installation qualification 
master production document, operational qualification 
and process capacity. 
Phase 2: This is the process validation phase. It is 
designed to verify that all established limits of the 
critical process parameter are valid and that satisfactory.  
Phase 3: Known as the validation maintenance Phase, it 
requires frequent review of all process related 
documents, including validation of audit reports, to 
assure that there have been no changes, deviations 
failures and modifications to the production process and 
that all SOPs, including change control procedures, 
have been followed and all lots or batches produced will 
meet their intended specifications. 
Various Approaches in Process Validation 
8
 
Process Design: The goal of this stage is to design a 
process suitable for routine commercial manufacturing 
that can consistently deliver a product that meets its 
quality attributes. 
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Process Qualification: This stage has two elements: 
a.design of the facility and qualification of the 
equipment and utilities and b.process performance 
qualification (PPQ). 
Continued Process Verification: The goal of the third 
stage is continual assurance that the process remains in 
a state of control (the validated state) during 
commercial manufacture. 
.  
2.5 Cleaning Validation 
Cleaning validation is the methodology used to assure 
that a cleaning process removes residues of the active 
pharmaceutical ingredient of the product manufactured 
in a piece of equipment, the cleaning aids and ensures 
that all residues are removed to predetermined levels 
(product contamination below the acceptable level) to 
ensure the quality of the next product to be 
manufactured. 
 2.6 Vendor Validation 
It includes the qualification of the vendor who provides 
all the active material and the excipients required for 
formulation. 
2.7 Computer System Validation 
Computer validation includes qualification of all 
software and hardware, which has a direct or indirect 
impact on the quality of a product. 
Responsible Authorities for Validation 
9
 
 Head of quality assurance. 
 Head of Production. 
 Head of Quality Control. 
 Head of engineering & Maintenance.  
 Specialist validation member of other related areas  
Validation Protocol 
10
 
The validation protocol should be numbered, signed and 
dated, and should contain as a minimum the following 
information: 
 Title 
 Objective & Scope 
 Responsibility 
 Protocol Approval 
 Validation Team 
 Product Composition 
 Process Flow Chart 
 Manufacturing Process 
 Review of Equipments / Utilities 
 Review of Raw Materials and Packing Materials 
 Review of Analytical and Batch Manufacturing 
Records 
 Review of Batch Quantities for Validation (Raw 
Materials & Packing Materials) 
 HSE Requirements 
 Review of Process Parameters Validation 
Procedure 
 Sampling Location 
 Documentation 
 Acceptance Criteria 
 Summary 
 Conclusion. 
 
Validation Master Plan
11
 
A validation master plan is a document that summarizes 
the company’s overall philosophy, intentions and 
approaches to be used for establishing performance 
adequacy. The Validation Master Plan should be agreed 
upon by management. Validation in general requires 
preparation and careful planning of the various steps in 
the process. In addition, all work should be carried out 
in a structured way according to formally authorized 
standard operating procedures. All observations must be 
documented and where possible must be recorded as 
actual numerical results. The validation master plan 
should provide an overview of the entire validation 
operation, its organizational structure, its content and 
planning. All validation activities relating to critical 
technical operations, relevant to product and process 
controls within a firm should be included in the 
validation master plan. It should comprise all 
prospective, concurrent and retrospective validations as 
well as re-validation. The Validation Master Plan 
should be a summary document and should therefore be 
brief, concise and clear. It should not repeat information 
documented elsewhere but should refer to existing 
documents such as policy documents, SOP’s and 
validation protocols and reports. 
Pre-Requisites for Successful Validation 
There are some elements or tools that are required for 
conducting effective validations which are discussed in 
the following sections: 
1) Understanding: The single most important 
element required is a good understanding of what 
validation is. This understanding activity must be 
anchored by sufficient years of practical experience 
and knowledge. It will permit sound and logical 
decisions even under most intense situations 
12
.  
2) Communication: Communication is one of the 
best methods of improving understanding and is 
essential for any activity that requires more than 
one resource to complete as conducting effective 
validation involves multi-departments. 
3) Co-operation,Plan and Focus: Multiple 
departments are involving and   interacting during 
the validation process such as Quality Assurance, 
Production, Quality Control, Maintenance, project 
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management, accounting etc so they should have a 
commendable co-operation, focus and plan in order 
to get good team synergy. 
4) Experience:  To get success in validation program 
well experienced validation team are required. 
5) Resources: Resources means personnel who will 
plan and execute equipment on which validations 
will be performed on materials with which to 
conduct validations. 
6) Budget: It is important to understand that a 
successful validation must be done to completion 
and it should not be limited by a budget as 
validations cost money.  
7) Standard Operating Procedures (SOP’s): The 
SOPs capture activities that routinely occur within 
an organization so all the concerned department 
must be trained about SOPs and its implementation. 
8) Quality Control lab support: During the 
validations, some laboratory testing will be 
required which are handled by the QC so well 
facilitated qc lab is required to get results in 
expected time. 
9) Permission to conduct preliminary runs. 
10) Realistic completion dates. 
Objective of Process Validation 
13
 
1. To reduce variation between various batches. 
2. To provide a high degree of assurance of quality of 
the product. 
3. To decrease the risk of defect costs and regulatory 
noncompliance. 
4. To ensure the consistency of the manufacturing 
operation and reproducibility of the process. 
5. To demonstrate the robustness of the process. 
6. A fully validated process may require less in-
process controls and end product testing. 
7. To ensure the existence of all necessary quality 
assurance system within organization. 
Guidelines for process validation of tablets:
14
 
Typical pharmaceutical manufacturing processes 
comprise a serious of unit operations which includes: 
machinery, methods, people, material, measuring 
systems and environmental conditions, etc. To assure 
batch uniformity and integrity of drug products, written 
procedures need to be established and followed to test 
for each batch. Such control procedures are established 
to monitor the output and to validate the performance of 
the manufacturing processes that may be responsible for 
causing variability in the characteristics of in-process 
material and the drug product.
15
. 
Process control[4] 
Modern methods of process control in process 
validation are  
➢ Six sigma 
➢ Process capability index 
➢ Statistical process control (SPC) include: 
Sampling plan, experimental design, variation 
reduction, process capability analysis, process 
improvement plans,SPC will not improve a poorly 
designed product’s reliability, but can be used as a tool 
to maintain the consistency of how the product is made. 
In-process specifications establishment: In process 
specifications are established based on the previous 
acceptable process average and process variability 
determined by the application statistical procedures 
wherever appropriate. Samples must represent the batch 
under analysis. Statistical quality control criteria as 
condition of approval and release of batch must meet its 
predetermined specifications. 
For Process validation of tablet, each and every step 
involved during formulation of tablet should be taken 
into consideration. Following are the steps and the 
parameter which should be considered during process 
validation of tablet. 
A. Raw Material Validation: 
Active pharmaceutical ingredient 
 Excipients 
 Variation in raw material is one of the major causes 
of product variation or deviation from specification 
 API may represent the most uncontrollable 
component. 
 State a good pre-formulation program at early 
phase of product 
 Critical steps in the development cycle 
Chemical characteristics 
 Drug impurities, Impurity levels. 
 Physical properties: 
Drug morphology, solubility, particle size/surface 
area, shape, drug density, hygroscopic nature 
B. Analytical method Validation: 
 Accuracy 
 Precision 
 Specificity 
 Intra / Inter day variance 
 Between operator variation 
 Between instrument variation 
C. Process evaluation, selection and validation: 
16
 
1. Dispensing: 
Dispensing is done prior to formulation. Ensure 
dispensing booth is clean and line clearance is given as 
per SOPs. Ensure that balance is calibrated and ensure 
that the expiry date of product to be released is later 
than that of batch expiry date. Check and ensure that the 
all materials are issued as per BMR. And all the rooms 
such as granulation room, Compression room, coating 
room, packing room etc are clean and line clearance has 
been done prior to processing. 
2. Mixing or Blending 
Materials that have similar physical properties will be 
easier to form a uniform mix or blend and will not 
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segregate as readily as materials with large differences. 
Parameters to be considered are: 
 Mixing or blending technique: Diffusion (tumble), 
convection (planetary or high intensity), or 
pneumatic (fluid bed). 
 Mixing or blending speed: Determine the intensity 
(low/high shear) and/or speed (rpm) of the mixing 
or blending. Mixing the drug and excipient will 
require more intense mixing than adding the 
lubricant to the final blend. 
 Mixing or blending time: The mixing or blending 
time will be dependent on the mixing or blending 
technique and speed. 
 Drug uniformity: Content uniformity is usually 
performed to determine the uniformity of drug 
throughout the mix or blend. Representative 
samples should be taken throughout the mix or 
blend. The sampling technique and handling of the 
materials are key in obtaining valid content 
uniformity results. For the final lubricated granules, 
the sample taken should be equivalent to the weight 
of a single tablet. 
 Excipient uniformity: Lubricant,Color 
 Equipment capacity/load. 
3. Wet Granulation 
The type of wet granulation technique used will 
produce granules with different physical properties and 
will require monitoring of different processing 
parameters. 
 Binder addition. 
 Binder concentration: The optimal binder 
concentration will need to be determined for the 
formulation. If the binder is to be sprayed, the 
binder solution needs to be dilute enough so that it 
can be pumped through the spray nozzle. It should 
also be sufficiently concentrated to form granules 
without over wetting the materials. 
 Amount of binder solution/granulating solvent. 
 Binder solution/granulating solvent addition rate. 
 Mixing time. 
 Granulation end point: Granulation end point is 
determined or controlled by granulation end point 
equipment (e.g., ammeter) or by specifying critical 
processing parameters. For example, a drug or 
excipient mixture may be granulated by adding a 
predetermined amount of water (granulating 
solution) at a certain rate. The granulation is 
completed after mixing for a set time after the 
water has been added. 
4. Wet Milling 
Wet granules need to be milled to break up the lumps 
and enhance drying of the granulation. Factors to be 
consider are: 
 Equipment size and capacity. 
 Screen size. 
 Feed rate. 
 Mill Speed. 
5. Drying 
The type of drying technique (e.g., tray, fluid bed, and 
microwave) required for the formulation needs to be 
determined and justified. The type of technique may be 
dependent on drug or formulation properties and 
equipment availability. Changing dryer techniques 
could affect such tablet properties as hardness, 
disintegration, dissolution, and stability. The optimal 
moisture content of the dried granulation needs to be 
determined. High moisture content can result in Tablet 
picking or sticking to tablet punch surfaces and Poor 
chemical stability as a result of hydrolysis. An over 
dried granulation could result in poor hardness and 
friability. 
 Inlet/outlet temperature. 
 Moisture uniformity: Heat uniformity of the dryer, 
amount of granulation per tray, and incomplete 
fluidization of the bed are factors that could affect 
the moisture uniformity of the granulation. 
 Equipment capability/capacity: A larger load will 
require more moisture to be removed on drying and 
will affect the drying time. 
 Airflow. 
6. Milling 
The milling operation will reduce the particle size of the 
dried granulation. The resultant particle size distribution 
will affect such material properties as flow, 
compressibility, disintegration, and dissolution. An 
optimal particle size/size distribution for the 
formulation will need to be determined. Factors to 
consider in milling are: 
 Mill type: impact or screen. 
 Screen size: The screen size will affect the particle 
size. A smaller screen size will produce a smaller 
particle size and a greater number of fines. 
 Mill speed. 
 Feed rate. 
7. Lubrication 
 Grade of the lubricant used. 
 Compatibility with other ingredients. 
 Mixing time: 
 Amount of lubricant added: Too much lubricant 
will form hydrophobic layer on the tablet resulting 
in dissolution problems. 
8. Tablet Compression 
Compression is a critical step in the production of a 
tablet dosage form. The materials being compressed 
will need to have adequate flow to flow from the hopper 
onto the feed frame and into the dies. Inadequate flow 
can result in “rat holing” in the hopper and/or 
segregation of the blend in the hopper/feed frame. This 
can cause tablet weight and content uniformity 
problems. Factors to consider during compression are as 
follows: 
 Tooling: The shape, size, and concavity of the 
tooling should be examined based on the 
Parajuli et al                                            Journal of Drug Delivery & Therapeutics. 2015; 5(6):1-7 6 
© 2011-15, JDDT. All Rights Reserved                                                   ISSN: 2250-1177                                             CODEN (USA): JDDTAO 
formulation properties and commercial 
specifications. 
 Compression speed: The formulation should be 
compressed at a wide range of compression speeds 
to determine the operating range of the compressor. 
 Compression/ejection force: The compression 
profile for the tablet formulation will need to be 
determined to establish the optimal compression 
force to obtain the desired tablet hardness. 
The following in-process tests should be examined 
during the compression stage: 
 Appearance 
 Hardness, Thickness 
 Tablet weight 
 Friability 
 Disintegration Time 
 Weight uniformity 
9. Tablet Coating 
Tablet coating can occur by different techniques (sugar, 
film, or enteric) where film coating is the most 
common. Factors to be considered for tablet coating are: 
 Tablet properties: Tablet properties such as 
hardness, shape, are important to obtain a good 
film-coated tablet. 
 Equipment type. 
  rpm of the coating pan. 
 Spray guns: Angle of spray. 
 Application/spray rate: The optimal spray rate 
should be determined. Spraying too fast will cause 
the tablets to become over wet, resulting in 
clumping of tablets and possible dissolution of the 
tablet surface. Spraying too slowly will cause the 
coating materials to dry prior to adhesion to the 
tablets. 
 Tablet flow. 
 Inlet/outlet temperature and airflow. 
 Coating solution: The concentration and viscosity 
of the coating solution will need to be determined. 
The stability of the coating solution should be 
investigated to establish its shelf life. 
 Coating weight: A minimum and maximum coating 
weight should be established for the tablet to 
provide a uniform appearance. 
 Residual solvent level: If solvents are used for 
tablet coating, the residual solvent level will need 
to be determined.  
.10. In-process tests 
 Moisture content of “dried granules” 
 Granulation particle size distribution 
 Blend uniformity 
 Individual tablet/capsule weight 
 Tablet hardness and Tablet thickness 
 Disintegration 
 Impurity profile 
11. Finished product tests 
 Appearance 
 Tablet mottling 
 Picking of the monogram 
 Tablet filming 
 Capping of the tablets 
 Tablet colored 
 Assay. 
  Content uniformity 
 Beginning 
 Middle 
 End 
 Tablet hardness 
 Tablet friability 
 Impurity profile 
12. Labelling and packing: 
Check and record the temperature of the heating roller 
and sealing roller, over printing instructions on labels 
and cartons. Check and verify that price overprinted on 
label and carton is as per current price list. After 
ensuring the proper labeling of tablets, check, for 
correctness of cartons packing for the same. 
Finished product analysis and release: 
Finished product needs to be analyzed as per in-house 
specification and product released only after 
predetermined specifications and quality attributes. 
Process validation testing is generally done on the first 
three batches of product made in production-size 
equipment. Revalidation testing is only done when a 
“significant” change has occurred. 
Reason for choosing three consecutive batches for 
Validation: 
Generally it is considered if we get the desired quality 
in first batch it is accidental, second batch quality is 
regulator, and quality in third batch is validation. When 
two batches are taken as validation the data will not be 
sufficient for evaluation and to prove reproducibility 
because statistical evaluation cannot be done on two 
points, it needs minimum three points because two 
points always draw a straight line. Therefore, minimum 
three consecutive batches are evaluated for validation of 
manufacturing process. More than three batches can be 
taken in validation but it involves the cost and time. 
Final Process Validation Report 
17
 
At the conclusion of validation activities, a final report 
should be prepared. This report should summarize and 
reference all protocols and results. It should derive 
conclusions regarding the validation status of the 
process and necessary recommendation for routine 
process. The final report should be reviewed and 
approved by the validation team and appropriate 
management. 
 A validation report shall be prepared to assess the 
adherence to the protocol after execution of 
batches. 
 Data can be collected in pre design format during 
execution wherever application but not limited to. 
 Name of ingredients, quality of ingredients used 
and product batch number, Name of the equipments 
used at each processing stage, equipments numbers 
and make/model/capacity of the equipments shall 
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be checked against the formulation order of the 
validation batch processing records. 
 The environmental condition during batch 
execution at each processing stage shall be checked 
against the formulation order of the validation 
batch processing records. 
 Stage of process, details of process variables the 
respective observations and recommendations shall 
be checked against the formulation order of the 
validation batch processing records. 
 Any work done in addition to that specific in the 
protocol or any deviation from the protocol should 
be formally noted along with an explanation. 
 All sampling location shall be specified. 
 The actual yield obtained at different stages shall 
be checked against the formulation order of the 
validation batch processing records. 
CONCLUSION: 
It is concluded that Process validation is a step to assure 
the identity, strength, purity, safety and efficacy of 
pharmaceutical drug products, and it is the most 
common word in the drug development, manufacturing 
and specification of finished product. Process validation 
is major requirement of cGMPs regulation for the 
process efficiency. The multidisciplinary validation 
team must identify the product and process 
characteristics that must be studied and incorporate 
specific validation tests to ensure that that product will 
meet all quality, manufacturing, and regulatory 
requirements. The total program should begin with 
validation of the active pharmaceutical ingredient (API) 
characteristics so that this material will be uniform 
batch after batch, providing a solid pillar under which 
the dosage form will be built. The parameters chosen 
must be relevant indicators of a controlled process. 
Continued awareness of validation requirements and a 
diligent application of validation principles will thus 
help to ensure that pharmaceutical products will be able 
to be developed and produced with the quality and 
reproducibility required from regulatory agencies across 
the world. 
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